$CCEL
CRYO CELL INTERNATIONAL INC

2022 Q1 Form 10-Q Financial Statement

#000095017022005662 Filed on April 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1 2020 Q4
Revenue $7.259M $6.861M $7.541M
YoY Change 5.8% -9.97% -5.39%
Cost Of Revenue $2.103M $2.012M $2.313M
YoY Change 4.52% -19.61% -1.65%
Gross Profit $5.155M $4.848M $5.227M
YoY Change 6.33% -5.26% -6.95%
Gross Profit Margin 71.02% 70.67% 69.32%
Selling, General & Admin $3.376M $3.433M $3.490M
YoY Change -1.67% -11.28% -11.46%
% of Gross Profit 65.48% 70.81% 66.76%
Research & Development $147.2K $6.190K $7.060K
YoY Change 2278.35% 8.18% -58.13%
% of Gross Profit 2.86% 0.13% 0.14%
Depreciation & Amortization $396.1K $72.49K $87.60K
YoY Change 446.44% -24.3% -9.55%
% of Gross Profit 7.68% 1.5% 1.68%
Operating Expenses $3.523M $3.440M $1.763M
YoY Change 2.43% -11.26% -55.99%
Operating Profit $1.470M $1.235M $3.464M
YoY Change 19.04% -1.11% 114.81%
Interest Expense $306.1K $280.2K -$349.6K
YoY Change 9.23% -23.29% -0.6%
% of Operating Profit 20.82% 22.69% -10.09%
Other Income/Expense, Net -$314.7K -$282.8K $20.00
YoY Change 11.3% -8.7% -99.93%
Pretax Income $1.156M $952.5K $1.831M
YoY Change 21.33% 1.4% 41.77%
Income Tax $323.6K $258.9K $630.8K
% Of Pretax Income 28.0% 27.18% 34.46%
Net Earnings $832.0K $693.6K $1.200M
YoY Change 19.96% 0.96% 42.0%
Net Earnings / Revenue 11.46% 10.11% 15.91%
Basic Earnings Per Share $0.10 $0.09
Diluted Earnings Per Share $0.10 $0.08 $147.2K
COMMON SHARES
Basic Shares Outstanding 8.527M 7.571M 7.546M
Diluted Shares Outstanding 8.748M 8.199M

Balance Sheet

Concept 2022 Q1 2021 Q1 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.617M $11.36M $11.17M
YoY Change -76.97% 21.22% 50.01%
Cash & Equivalents $2.145M $11.28M $10.36M
Short-Term Investments $472.4K $85.90K $807.0K
Other Short-Term Assets $483.5K $825.4K $244.7K
YoY Change -41.42% 314.63% -6.03%
Inventory $927.6K $868.3K $927.3K
Prepaid Expenses $537.7K $611.6K
Receivables $5.152M $5.639M $6.323M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.717M $18.70M $18.56M
YoY Change -48.03% 10.66% 20.59%
LONG-TERM ASSETS
Property, Plant & Equipment $3.805M $2.610M $1.641M
YoY Change 45.79% 47.06% -11.14%
Goodwill $1.941M $1.941M
YoY Change 0.0%
Intangibles $1.536M $1.182M
YoY Change -5.42%
Long-Term Investments $308.0K $308.0K $308.0K
YoY Change 0.0% 0.0% 0.0%
Other Assets $41.29M $80.15M $26.00M
YoY Change -48.49% 207.57% 1.37%
Total Long-Term Assets $45.09M $86.57M $27.64M
YoY Change -47.91% 211.0% 0.53%
TOTAL ASSETS
Total Short-Term Assets $9.717M $18.70M $18.56M
Total Long-Term Assets $45.09M $86.57M $27.64M
Total Assets $54.81M $105.3M $46.20M
YoY Change -47.93% 135.33% 7.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.848M $860.1K $957.4K
YoY Change 114.82% -37.73% -30.07%
Accrued Expenses $2.104M $3.697M $2.898M
YoY Change -43.08% 36.22% 38.99%
Deferred Revenue $9.057M $9.183M
YoY Change 3.47%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.129M $3.100M $3.100M
YoY Change -63.57% 0.0% 0.0%
Total Short-Term Liabilities $16.39M $29.84M $16.41M
YoY Change -45.09% 85.72% 6.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.086M $2.841M
YoY Change -100.0% -78.73% -51.48%
Other Long-Term Liabilities $34.17M $76.03M $32.45M
YoY Change -55.06% 119.35% -5.69%
Total Long-Term Liabilities $34.17M $77.11M $32.45M
YoY Change -55.69% 122.48% -5.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.39M $29.84M $16.41M
Total Long-Term Liabilities $34.17M $77.11M $32.45M
Total Liabilities $50.56M $107.0M $48.87M
YoY Change -52.73% 110.84% -1.95%
SHAREHOLDERS EQUITY
Retained Earnings -$15.90M -$18.82M
YoY Change -16.15%
Common Stock $41.80M $36.72M
YoY Change 1.84%
Preferred Stock
YoY Change
Treasury Stock (at cost) $21.64M $20.56M
YoY Change 0.0%
Treasury Stock Shares $6.190M $6.094M $6.094M
Shareholders Equity $4.251M -$1.695M -$2.665M
YoY Change
Total Liabilities & Shareholders Equity $54.81M $105.3M $46.20M
YoY Change -47.93% 135.33% 7.73%

Cashflow Statement

Concept 2022 Q1 2021 Q1 2020 Q4
OPERATING ACTIVITIES
Net Income $832.0K $693.6K $1.200M
YoY Change 19.96% 0.96% 42.0%
Depreciation, Depletion And Amortization $396.1K $72.49K $87.60K
YoY Change 446.44% -24.3% -9.55%
Cash From Operating Activities $1.507M $2.662M $2.977M
YoY Change -43.4% 1.78% 148.3%
INVESTING ACTIVITIES
Capital Expenditures $647.6K $11.98K -$47.56K
YoY Change 5306.89% 72.07% -69.31%
Acquisitions
YoY Change
Other Investing Activities -$5.406M -$150.0K $99.36K
YoY Change 3503.73% -438.42%
Cash From Investing Activities -$6.053M -$162.0K $51.80K
YoY Change 3637.07% 2226.94% -128.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $829.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.572M -1.583M -775.0K
YoY Change -0.72% 115.72% -57.24%
NET CHANGE
Cash From Operating Activities 1.507M 2.662M 2.977M
Cash From Investing Activities -6.053M -162.0K 51.80K
Cash From Financing Activities -1.572M -1.583M -775.0K
Net Change In Cash -6.118M 916.7K 2.254M
YoY Change -767.45% -51.1% -382.49%
FREE CASH FLOW
Cash From Operating Activities $1.507M $2.662M $2.977M
Capital Expenditures $647.6K $11.98K -$47.56K
Free Cash Flow $859.1K $2.650M $3.024M
YoY Change -67.58% 1.59% 123.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-02-28
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-40767
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
CRYO-CELL INTERNATIONAL, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3023093
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
700 Brooker Creek Blvd
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
CY2022Q1 dei City Area Code
CityAreaCode
813
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
749-2100
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2022Q1 dei Trading Symbol
TradingSymbol
CCEL
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8460380
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2144631
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8263088
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
472369
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
75412
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3126474
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3078439
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5151565
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
537726
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
558413
CY2022Q1 us-gaap Inventory Net
InventoryNet
927568
CY2021Q4 us-gaap Inventory Net
InventoryNet
921213
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
483542
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
711208
CY2022Q1 us-gaap Assets Current
AssetsCurrent
9717401
CY2021Q4 us-gaap Assets Current
AssetsCurrent
15782507
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3804823
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3230204
CY2022Q1 ccel Duke License Agreement
DukeLicenseAgreement
14411608
CY2021Q4 ccel Duke License Agreement
DukeLicenseAgreement
14651802
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1535597
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1559693
CY2022Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
9655372
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
9695363
CY2022Q1 us-gaap Goodwill
Goodwill
1941411
CY2021Q4 us-gaap Goodwill
Goodwill
1941411
CY2022Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
12010133
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
12010133
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
839889
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
916493
CY2022Q1 ccel Deposits And Other Assets
DepositsAndOtherAssets
584064
CY2021Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
566470
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41286074
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41649365
CY2022Q1 us-gaap Assets
Assets
54808298
CY2021Q4 us-gaap Assets
Assets
60662076
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1847733
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1489774
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2103953
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3057386
CY2022Q1 us-gaap Notes Payable Current
NotesPayableCurrent
1129454
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1898065
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
315860
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
312067
CY2022Q1 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
1933004
CY2021Q4 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
4957591
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9057085
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9358696
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16387089
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21073579
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
32153053
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
31274214
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
610938
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
727371
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
530941
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
610989
CY2022Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2021Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34169932
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
35404183
CY2022Q1 us-gaap Liabilities
Liabilities
50557021
CY2021Q4 us-gaap Liabilities
Liabilities
56477762
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14675772
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8490898
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14665772
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8557326
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
146758
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
146658
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41650379
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41586583
CY2022Q1 us-gaap Treasury Stock Value
TreasuryStockValue
21641714
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
20812734
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15904146
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16736193
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4251277
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4184314
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54808298
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60662076
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7258531
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6860617
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2103202
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2012197
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3375954
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3433312
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-116433
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
152394
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
147220
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6190
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
278166
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
21263
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
5788109
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
5625356
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1470422
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1235261
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-8642
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-2576
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25
CY2022Q1 us-gaap Interest Expense
InterestExpense
306095
CY2021Q1 us-gaap Interest Expense
InterestExpense
280219
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-314728
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-282770
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1155694
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
952491
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
323647
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
258901
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
832047
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
693590
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8527031
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7570913
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8748183
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8198591
CY2022Q1 us-gaap Profit Loss
ProfitLoss
832047
CY2021Q1 us-gaap Profit Loss
ProfitLoss
693590
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
396112
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
72489
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-116433
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
152394
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-8642
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-2576
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
31896
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
84818
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
164388
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
90854
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
6389
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
19682
CY2022Q1 ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
76604
CY2021Q1 ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
66620
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
62780
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-593114
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-20687
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-100975
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-33636
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-109928
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-227666
CY2021Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
70028
CY2022Q1 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
17594
CY2021Q1 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
98675
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
357959
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-97258
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-953433
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
559087
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-76255
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-65504
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
577228
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
447380
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1506759
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2662042
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
647637
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11978
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
150000
CY2022Q1 ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
5000000
CY2022Q1 ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
405599
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6053236
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-161978
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
828980
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
775000
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1775000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
191622
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1571980
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1583378
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6118457
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
916686
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8263088
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10361125
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2144631
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11277811
CY2021Q1 ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
780070
CY2021Q1 ccel Patent Option Agreement Credit To Purchase Of Patents And Licenses
PatentOptionAgreementCreditToPurchaseOfPatentsAndLicenses
500000
CY2021Q1 ccel Liabilities Incurred For The Purchase Of Patents And Licenses
LiabilitiesIncurredForThePurchaseOfPatentsAndLicenses
15242161
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4184314
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
31896
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
828980
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
832047
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4251277
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2665135
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
191622
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
84818
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
693590
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-1695105
CY2022Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
41210138
CY2022Q1 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9057085
CY2022Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2017Q2 ccel Reimbursement Of Personal Expenses
ReimbursementOfPersonalExpenses
10000
CY2022Q1 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
15152
CY2021Q1 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
13507
CY2022Q1 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
24589
CY2021Q1 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
18262
CY2022Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
553116
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
535522
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5151565
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9057085
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9358696
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
32153053
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
31274214
CY2022Q1 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2021Q1 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
535522
CY2022Q1 ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
24589
CY2022Q1 ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
6995
CY2022Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
553116
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
CY2022Q1 ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
8749914
CY2022Q1 ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
8851522
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5151565
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
40632910
CY2022Q1 ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
3997047
CY2022Q1 ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
3419819
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
41210138
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
466141
CY2021Q1 ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
18262
CY2021Q1 ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
6033
CY2021Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
478370
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322960
CY2021Q1 ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
8402508
CY2021Q1 ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
9086476
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5638992
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36384360
CY2021Q1 ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
3711251
CY2021Q1 ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
3263871
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36831740
CY2021Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1164499
CY2022Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2022Q1 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2021Q1 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2022Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
85000
CY2022Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-9000
CY2021Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-3000
CY2022Q1 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Product Warranty and Cryo-Cell Cares</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Program</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> payment warranty to a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. In accordance with ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method; therefore, the transaction price does not reflect any expectation of service level credits at February 28, 2022 and November 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</span></p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2022Q1 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2022Q1 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
6389
CY2021Q1 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
19682
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7258531
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6860617
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2103202
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2012197
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1470422
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1235261
CY2022Q1 us-gaap Interest Expense
InterestExpense
306095
CY2021Q1 us-gaap Interest Expense
InterestExpense
280219
CY2022Q1 us-gaap Assets
Assets
54808298
CY2021Q4 us-gaap Assets
Assets
60662076
CY2021Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1164499
CY2022Q1 ccel Inventory Collection Kits
InventoryCollectionKits
29378
CY2021Q4 ccel Inventory Collection Kits
InventoryCollectionKits
42998
CY2022Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2022Q1 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
10582940
CY2021Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
10616576
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1535597
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1559693
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
CY2022Q1 us-gaap Notes Payable
NotesPayable
1133433
CY2021Q4 us-gaap Notes Payable
NotesPayable
1908433
CY2022Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
3979
CY2021Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
10368
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
1129454
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
1898065
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
12146
CY2021Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
40538
CY2022Q1 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
6389
CY2021Q1 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
19682
CY2022Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
18535
CY2021Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
60220
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
832047
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
693590
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8527031
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7570913
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
221152
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
627678
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8748183
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8198591
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11484
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39000
CY2022Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
474927
CY2022Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y6M29D
CY2022Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.89
CY2022Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
420911
CY2022Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
5.46
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
63034
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.99
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
4602
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
6.27
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
4416
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
7.98
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
54016
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.63
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company’s 2012 Stock Plan and vested 1/3 upon grant, 1/3 on December 1, 2020 and the remaining 1/3 on November 30, 2021.
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
CY2022Q1 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2022Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
6190384
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6113956
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
839889
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
916493
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
315860
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
312067
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
530941
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
610989
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
846801
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
923056
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
255137
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
313996
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
295086
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
24591
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
42009
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
846801
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M29D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y29D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
85964
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
71566
CY2022Q1 ccel Covid19
Covid19
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Note 12 – COVID-19</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (“COVID-19”) outbreak. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The pandemic and government measures taken in response have had a significant adverse impact, both direct and indirect, on our business and the economy. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company faces various risks related to health epidemics, pandemics and similar outbreaks, including the global outbreak of COVID-19. The Company believes it has taken appropriate steps to minimize the risk to our employees and to maintain normal business operations and continues to actively monitor the global outbreak and spread of COVID-19 and continues to take steps to mitigate the potential risks to us posed by its spread and related circumstances and impacts. While the ultimate health and economic impact of COVID-19 remains highly uncertain, we expect that our business operations and results of operations, including our net sales, earnings and cash flows, may continue to be impacted by decreases in new client sales. We cannot predict the timing and speed of the recovery, and any delay in the recovery could significantly impact our future results.</span>
CY2020Q2 us-gaap Line Of Credit
LineOfCredit
350000
CY2020Q2 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000
CY2020Q4 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000
CY2022Q1 ccel Expected Days To Complete Construction
ExpectedDaysToCompleteConstruction
P90D
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20000000

Files In Submission

Name View Source Status
0000950170-22-005662-index-headers.html Edgar Link pending
0000950170-22-005662-index.html Edgar Link pending
0000950170-22-005662.txt Edgar Link pending
0000950170-22-005662-xbrl.zip Edgar Link pending
ccel-20220228.htm Edgar Link pending
ccel-20220228.xsd Edgar Link pending
ccel-20220228_cal.xml Edgar Link unprocessable
ccel-20220228_def.xml Edgar Link unprocessable
ccel-20220228_htm.xml Edgar Link completed
ccel-20220228_lab.xml Edgar Link unprocessable
ccel-20220228_pre.xml Edgar Link unprocessable
ccel-ex10_4.htm Edgar Link pending
ccel-ex31_1.htm Edgar Link pending
ccel-ex31_2.htm Edgar Link pending
ccel-ex31_3.htm Edgar Link pending
ccel-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending